Research programme: oncolytic virus therapeutics - Neotropix

Drug Profile

Research programme: oncolytic virus therapeutics - Neotropix

Alternative Names: NTX-100; NTX-250; NTX-400; NTX-420; NTX-500; NTX-800

Latest Information Update: 16 Jun 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neotropix
  • Class Oncolytic viruses
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jun 2011 Research programme: oncolytic virus therapeutics - Neotropix is available for licensing.
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 05 Sep 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top